Article

Fracture risk heightened in inflammatory disorders

Persons who have chronic inflammatory diseases, such as rheumatologic disorders and inflammatory bowel diseases (IBD), are at increased risk for fracture.

Persons who have chronic inflammatory diseases, such as rheumatologic disorders and inflammatory bowel diseases (IBD), are at increased risk for fracture. Risk factors include treatment with long-term systemic corticosteroids, which may lead to decreased bone mineral density; microarchitectural weakness; bone remodeling; bone turnover; and mineralization.

Weiss and colleagues examined the incidence of hip and vertebral fractures in persons with a spectrum of rheumatologic disorders and IBD, including rheumatoid arthritis, systemic lupus erythematosus, Crohn disease, and ulcerative colitis. In all, 53,108 patients who had fractures were compared with 370,602 age- and sex-matched controls.

The risk of fracture was higher for patients with a rheumatologic disorder than for those with IBD. There was a statistically significant increase in risk of fracture for all rheumatologic diseases (odds ratio range, 2.6 for systemic sclerosis to 4 for ankylosing spondylitis [AS]). The largest increased risk of vertebral fractures was seen in AS and of hip fractures in juvenile idiopathic arthritis. The risk was increased in persons with Crohn disease or ulcerative colitis compared with controls and in patients who had a diagnosis of hypertension.

The authors noted that fracture prevention strategies may be of benefit in patients with these disorders and warrant further research.

Related Videos
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
© 2024 MJH Life Sciences

All rights reserved.